United States
Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT - now approved for the treatment of allergic dermatitis! Learn more

Together, we’re changing the way we approach canine pruritus.

Together, we’re changing the way we approach canine pruritus.

Itch can erode cherished bonds...
and treatment has historically required trade-offs between efficacy, safety and cost

Itch takes an emotional toll on owners—and can affect their
relationships with the veterinarian

  • Itch is the #1 reason for veterinarian visits for dogs1
  • 88% of owners have tried at-home itch treatments (up to 15 treatments) before bringing dog to the clinic2
  • Owners see veterinarians for real relief, immediately—rather than recommendations for treatments they could have tried at home3

Diagnosis begins with relief

Fast relief reassures the owner, inspires trust in the veterinarian

The right itch treatment helps you diagnose to completion by allowing the workup to proceed without interference—while providing patient relief and comfort

With the right approach, veterinarians can get back to doing what they love…caring for animals

See how transforming the approach to the pruritic dog protects the bonds that matter

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL Important Safety Information: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

SIMPARICA Indications: SIMPARICA kills adult fleas, and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), lxodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs 6 months of age or older and weighing 2.8 pounds or greater.

SIMPARICA Important Safety Information: Simparica is for use only in dogs, 6 months of age and older. Simparica may cause abnormal neurologic signs such as tremors, decreased conscious proprioception, ataxia, decreased or absent menace, and/or seizures. Simparica has not been evaluated in dogs that are pregnant, breeding or lactating. Simparica has been safely used in dogs treated with commonly prescribed vaccines, parasiticides and other medications. The most frequently reported adverse reactions were vomiting and diarrhea.

For more information, please see the full Prescribing Information.

CONVENIA Indications: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis.

CONVENIA Important Safety Information: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy.

For more information, please see the full Prescribing Information.

CYTOPOINT Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: 1. Data on file, Zoetis Pruritus Diary Survey Wave 2, 2015, Zoetis Inc. 2. Data on file, Pet Owner Quantitative Market Research, 2013, Zoetis Inc. 3. Data on file, Pruritus Market Opportunity, 2015, Zoetis Inc.

The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2018 Zoetis Services LLC. All rights reserved ZPC-00064